1199.225 open label extension study of nintedanib in SSc-ILD
An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
Duration of Study in the UK
3 years, 3 months, 29 days
This is an open-label extension study to investigate the long term safety of nintedanib in patients with ’Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD). Patients who have completed the parent trial 1199.214 (SENSCIS) as planned will be eligible for enrolment in this extension study. The trial will last approximately 3 years and will end either when nintedanib is available on the market or will be made otherwise available to the patient. The study will be performed by investigators specialized in the treatment of SSc-ILD.
London - Hampstead Research Ethics Committee
Date of REC Opinion
18 Jan 2018